Britain and America have announced a major commercial pact that will guarantee no levies on UK medicine exports being sold in the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to raise spending on pharmaceuticals through the National Health Service (NHS). This pledge ensures that import taxes on these key products will be held at zero for a duration of 36 months.
This agreement comes after earlier threats to hike import taxes on patented drug imports, with figures floated up to double the cost.
"This agreement with the United Kingdom reinforces the worldwide climate for new treatments and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," an announcement noted.
Economic Significance
Medicines represent one of the the United Kingdom's biggest export categories to the United States, which is clearly the largest market for large British pharmaceutical firms.
Trade data reveal that in the 12 months prior to the third quarter, the UK exported medicines valued at £11.1bn to the US. This amount accounted for a significant portion of British export trade in that span.
"This agreement safeguards work, boosts funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," a government official commented.
Detailed British Pledges
The agreement involves several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to double overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must return to the NHS to stay within budget will be restricted at fifteen percent. Last year, refunds exceeded twenty percent.
Industry Background
This agreement follows a ongoing row between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
The disagreement were intensified by assertions that US customers were paying significantly more for the equivalent treatments than patients in the other developed nations.
In recent months, several large manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on drugs, noting that its spending on drugs had decreased as a proportion of its total funding over the previous ten-year period.
